Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Oftalmi Announces Recall of the Camolyn Eye Drops Product Line
US Oftalmi is conducting a voluntary nationwide recall of all Over-the-Counter Eye Drops and Nasal Drops. Products were packaged in 15 mL plastic bottles and were distributed nationwide to food and drug distributors for retail. These products are being recalled because conditions at the manufacturing facility cannot assure the sterility of the products. Products that are non-sterile have the potential to cause eye infections, which may affect the sight. The following products and lot numbers are being recalled: Camolyn Homeopathic - Lots 049036 and 087934 Camolyn Plus, Naphazoline + Chamomile 15 mL - Lots 037691 and 097420 Camolyn Refresh 15 mL - Lots 116636 and 107610 Camolyn-A, Naphazoline + Pheniramine 15 mL - Lots 057063, 058962, 106606, and 099487 For more information, please visit: [http://www.fda.gov/Safety/Recalls/ucm207735.htm
Learn More

NSAIDS (Motrin, Advil, Aleve) may reduce the ability of aspirin to prevent a second stroke.
A recently published article in the Journal of Clinical Pharmacology discusses the effects of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Motrin, Advil), and naproxen (Aleve), on the ability of aspirin to prevent a second stroke. Specifically, the article provides information suggesting that the use of these NSAIDS may decrease the effectiveness of aspirin for preventing the formation of new clots in patients who have previously had a stroke. For more information, please visit: http://jcp.sagepub.com/cgi/content/full/48/1/117
Learn More

Date Published Title Drug Source
2010-04-13 Oftalmi Announces Recall of the Camolyn Eye Drops Product Line Naphazoline FDA
2008-08-13 NSAIDS (Motrin, Advil, Aleve) may reduce the ability of aspirin to prevent a second stroke. Naproxen MediGuard CRT
2009-04-30 FDA Requires Additional Labeling for Over-the-Counter Pain Relievers and Fever Reducers Naproxen FDA
2009-10-18 Single Lot of Naproxen 500 mg Tablets Recalled Naproxen FDA
2009-05-04 New FDA Labeling for OTC Pain Relievers Also Applies to Patients Taking Combination Products FDA
2008-02-27 Risk of Clinically Significant Liver Injury Natalizumab FDA
2008-08-26 Two new cases of progressive multifocal leukoencephalopathy (PML) Natalizumab FDA
2009-09-17 Update on Risk of Progressive Multifocal Leukoencephalopathy (PML) in Tysabri Patients Natalizumab FDA
2010-01-29 Biogen Idec Announces Monthly Update of Tysabri Monitoring Program Natalizumab Manufacturer
2010-02-05 Risk of Progressive Multifocal Leukoencephalopathy (PML) Increases with the Number of Tysabri (Natalizumab) Infusions Received Natalizumab FDA
2011-04-25 FDA Issues Update on the Risk Of Progressive Multifocal Leukoencephalopathy With Tysabri Natalizumab FDA
2012-01-24 FDA Announces New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) Associated with Tysabri (Natalizumab) Natalizumab FDA
2010-04-15 Asthma and COPD Inhalers That Contain Ozone-depleting CFCs to be Phased Out; Alternative Treatments Available Nedocromil FDA
2008-09-18 FDA Stops Imports of Ranbaxy Products Nefazodone FDA
2007-09-10 Guidance on use in pregnant women and pediatric patients due to to process impurity FDA
2008-04-09 Updated safety information Manufacturer
2008-08-21 Inhaled insulin Exubera no longer available after September 1, 2008 Manufacturer
2010-01-26 Recall of GlucoPro Insulin Syringes Manufacturer
2011-05-26 FDA Issues Statement on the AIM-HIGH Trial Niacin FDA
2009-08-28 Study Supports Link Between Statins and Muscle Pain and Weakness Niacin and Simvastatin MediGuard CRT
Back to Consumer Med Safety